Blueprint Medicines Corp.
(NASDAQ : BPMC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.35%195.351.2%$486.61m
GILDGilead Sciences, Inc.
-1.56%71.210.9%$439.27m
BIIBBiogen Inc.
-0.75%313.181.3%$342.13m
ILMNIllumina, Inc.
-3.74%305.373.5%$328.61m
CELGCelgene Corporation
-1.50%79.401.2%$318.95m
VRTXVertex Pharmaceuticals Incorporated
-3.04%172.001.9%$229.07m
REGNRegeneron Pharmaceuticals, Inc.
-2.11%379.602.6%$219.24m
ALXNAlexion Pharmaceuticals, Inc.
-2.04%121.392.0%$213.67m
SRPTSarepta Therapeutics, Inc.
-2.31%129.5016.4%$162.15m
AAgilent Technologies, Inc.
-3.84%61.811.5%$148.97m
BMRNBioMarin Pharmaceutical Inc.
-4.48%98.894.4%$133.13m
LGNDLigand Pharmaceuticals Incorporated
-3.21%178.9523.3%$114.41m
EXASExact Sciences Corporation
-2.09%60.9525.3%$103.37m
ECYTEndocyte, Inc.
-0.09%23.502.1%$95.77m
NBIXNeurocrine Biosciences, Inc.
-2.53%106.415.1%$93.27m

Company Profile

Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.